These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20371477)

  • 21. Complement recruitment using bispecific diabodies.
    Kontermann RE; Wing MG; Winter G
    Nat Biotechnol; 1997 Jul; 15(7):629-31. PubMed ID: 9219263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid, continuous purification of proteins in a microfluidic device using genetically-engineered partition tags.
    Meagher RJ; Light YK; Singh AK
    Lab Chip; 2008 Apr; 8(4):527-32. PubMed ID: 18369506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of biosensor technology for the engineering of antibodies and enzymes.
    Huber A; Demartis S; Neri D
    J Mol Recognit; 1999; 12(3):198-216. PubMed ID: 10398410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tailor made enzymes by protein engineering--future prospects for biotechnological process development.
    Nair PM
    Hindustan Antibiot Bull; 1993; 35(1-2):94-110. PubMed ID: 8181958
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered antibodies.
    Hudson PJ; Souriau C
    Nat Med; 2003 Jan; 9(1):129-34. PubMed ID: 12514726
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical biology: More charges against aggregation.
    Vendruscolo M; Dobson CM
    Nature; 2007 Oct; 449(7162):555. PubMed ID: 17914388
    [No Abstract]   [Full Text] [Related]  

  • 29. Developing therapeutic proteins by engineering ligand-receptor interactions.
    Jones DS; Silverman AP; Cochran JR
    Trends Biotechnol; 2008 Sep; 26(9):498-505. PubMed ID: 18675482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
    Weisser NE; Hall JC
    Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineered protein a for the orientational control of immobilized proteins.
    Johnson CP; Jensen IE; Prakasam A; Vijayendran R; Leckband D
    Bioconjug Chem; 2003; 14(5):974-8. PubMed ID: 13129401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site-specific polymer modification of therapeutic proteins.
    Kochendoerfer GG
    Curr Opin Chem Biol; 2005 Dec; 9(6):555-60. PubMed ID: 16233987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
    Bauer S; Renner C; Juwana JP; Held G; Ohnesorge S; Gerlach K; Pfreundschuh M
    Cancer Res; 1999 Apr; 59(8):1961-5. PubMed ID: 10213507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.
    Wu C; Ying H; Grinnell C; Bryant S; Miller R; Clabbers A; Bose S; McCarthy D; Zhu RR; Santora L; Davis-Taber R; Kunes Y; Fung E; Schwartz A; Sakorafas P; Gu J; Tarcsa E; Murtaza A; Ghayur T
    Nat Biotechnol; 2007 Nov; 25(11):1290-7. PubMed ID: 17934452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Self-assembling peptides and proteins for nanotechnological applications.
    Rajagopal K; Schneider JP
    Curr Opin Struct Biol; 2004 Aug; 14(4):480-6. PubMed ID: 15313243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.
    Nygren PA
    FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered two-helix small proteins for molecular recognition.
    Webster JM; Zhang R; Gambhir SS; Cheng Z; Syud FA
    Chembiochem; 2009 May; 10(8):1293-6. PubMed ID: 19422008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.